Please wait a minute...
文章检索
预防医学  2019, Vol. 31 Issue (11): 1097-1099    DOI: 10.19485/j.cnki.issn2096-5087.2019.11.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
EV71疫苗疑似预防接种异常反应监测结果
潘雪娇1,符剑1,沈灵智1,吕华坤1,肖艳慧2,陈海平2,石煊雯2
1.浙江省疾病预防控制中心,浙江 杭州 310051;
2.中国生物技术股份有限公司
Surveillance results of adverse events following immunization of enterovirus 71 inactvated vaccine
PAN Xue-jiao*,FU Jian,SHEN Ling-zhi,LYU Hua-kun,XIAO Yan-hui,CHEN Hai-ping,SHI Xuan-wen
*Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou,Zhejiang 310051,China
全文: PDF(1000 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析6月龄~3岁儿童接种武汉生物制品研究所肠道病毒71型灭活疫苗(EV71疫苗)的疑似预防接种异常反应(AEFI)发生情况,评价该疫苗的安全性。方法 按照《全国疑似预防接种异常反应监测方案》要求,采用主动监测和被动监测结合的方式收集浙江省2017年9月—2018年10月接种EV71疫苗的6月龄~3岁儿童AEFI报告病例资料,采用描述流行病学方法分析人群特征、地区分布、接种剂次及接种后发生AEFI相关情况。结果 监测接种儿童107 503人,其中主动监测27 173人,被动监测80 330人。接种EV71疫苗后发生AEFI 288例,AEFI报告发生率为267.90/10万人;其中一般反应266例,报告发生率为247.43/10万剂;异常反应14例,报告发生率为13.02/10万剂;偶合症8例,报告发生率为7.44/10万剂;无严重AEFI病例。288例AEFI病例中,被动监测145例,报告发生率为180.51/10万剂;主动监测143例,报告发生率为526.26/10万剂。男童150例,女童138例,男女比为1.09∶1。浙江省各市均有AEFI病例报告,报告病例数居前三位的是金华市、台州市和杭州市,占全省报告病例数的50.69%。接种第1剂次后发生AEFI 202例,占70.14%;AEFI在接种日发生163例,占56.60%。266例一般反应主要表现为发热、红肿和硬结;14例异常反应临床损害均较轻,其中8例为过敏性皮疹,未发现其他严重异常反应。结论 6月龄~3岁儿童接种该疫苗后AEFI报告发生率为267.90/10万剂,无严重AEFI病例,该EV71疫苗安全性良好。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
潘雪娇
符剑
沈灵智
吕华坤
肖艳慧
陈海平
石煊雯
关键词 EV71疫苗;疑似预防接种异常反应;监测;疫苗安全性    
AbstractObjective To evaluate the safety of enterovirus 71(EV71)inactivated vaccines produced by Wuhan Institute of Bio Products through learning the incidence of adverse events following immunization(AEFI)in children aged 6 months to 3 years old after vaccination. Methods  According to the national requirement for vaccine safety monitoring program,data of AEFI cases after inoculated EV71 vaccines from September 2017 to October 2018 in Zhejiang Province was collected by combining active and passive monitoring. Demographic characteristics,space distribution,dose and incidence of AEFI were analyzed. Results A total of 107 503 children were included in this study,of which 27 173 were actively monitored and 80 330 were passively monitored. The monitoring results showed that 288 cases of AEFI occurred after inoculated EV71 vaccines,the reported incidence rate was 267.90/100 000. Of 288 cases,266 cases had common reactions(247.43/100 000),14 cases had abnormal reactions(13.02/100 000)and 8 cases had complications(7.44/100 000);145 cases were passively monitored(180.51/100 000)and 143 cases were actively monitored(526.26/100 000);150 cases were males and 138 cases were females,with the males to females ratio of 1.09∶1. The AEFI of EV71 vaccines were reported in all the cities of Zhejiang Province,with Jinhua,Taizhou and Hangzhou ranking the top three and accounting for 50.69% of all the reported cases. About 202 cases of AEFI(70.14%)occurred after the first dose of EV71 vaccines,and 163 cases(56.60%)occurred on the day of inoculation.Most of common reactions were fever,swelling and sclerosis. The harm of the reported abnormal reactions was mild,with 8 cases of anaphylactic rash and no other serious abnormal reactions were found. Conclusion The reported incidence rate of AEFI of the domestic EV71 vaccine in children aged from 6 months to 3 years is 267.90/100 000,without serious abnormal reactions,suggesting that the EV71 vaccine is safe.
Key wordsEnterovirus 71 inactivated vaccine    Adverse events following immunization    Surveillance    Vaccine safety
     出版日期: 2019-11-01
ZTFLH:  R186  
基金资助:浙江省医药卫生科技项目(2019KY053)
通信作者: 符剑,E-mail:jfu@cdc.zj.cn   
作者简介: 潘雪娇,硕士,主管医师,主要从事疫苗接种及安全性研究工作
引用本文:   
潘雪娇,符剑,沈灵智,吕华坤,肖艳慧,陈海平,石煊雯. EV71疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2019, 31(11): 1097-1099.
PAN Xue-jiao,FU Jian,SHEN Ling-zhi,LYU Hua-kun,XIAO Yan-hui,CHEN Hai-ping,SHI Xuan-wen. Surveillance results of adverse events following immunization of enterovirus 71 inactvated vaccine. Preventive Medicine, 2019, 31(11): 1097-1099.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2019.11.004      或      http://www.zjyfyxzz.com/CN/Y2019/V31/I11/1097
[1] 中华人民共和国国家卫生健康委员会.2017年全国法定传染病疫情概况[EB/OL].(2018-02-26) [2019-08-17]. http:// www.nhc.gov.cn/jkj/s3578/201802/de926bdb046749abb7b0a8e23d 929104.shtml.
[2] 吴晨,吴昊澄,丁哲渊,等.2008—2015年浙江省手足口病流行特征分析[J].疾病监测,2016,31(10):831-834.
[3] LI R,LIU L,MO Z,et al.An inactivated enterovirus 71 vaccine in healthy children[J].N Engl J Med,2014,370(9):829- 837.
[4] ZHU F,XU W,XIA J,et al.Efficacy,safety,and immunogenicity of an enterovirus 71 vaccine in China[J].N Engl J Med,2014,370(9):818-828.
[5] HU Y M,WANG X,WANG J Z,et al.Immunogenicity,safety,and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months[J].Clin Vaccine Immunol,2013,(12):1805-1811.
[6] 中华人民共和国卫生部,国家食品药品监督管理局.全国疑似预防接种异常反应监测方案[S].2010.
[7] 白云骅,李丽,张军楠,等.肠道病毒71型灭活疫苗上市后安全性主动监测[J].中国公共卫生,2017,33(4):65-67.
[8] 杜进发,钟革,陆伟才,等.2016—2017年广西肠道病毒71型灭活疫苗疑似预防接种异常反应监测结果分析[J].应用预防医学,2018,24(5):384-386.
[9] 汪志国,汤奋扬,高君,等.肠道病毒71型灭活疫苗上市后安全性监测与评价[J].江苏预防医学,2018,29(6):626- 629.
[10]辛秀梅,张金凤,热孜万,等.新疆疑似预防接种异常反应主动监测项目结果分析[J].中国妇幼保健,2012,27(24):3747-3749.
[11]沈金花,陆红梅,黄卓英,等.上海市松江区乙型肝炎疫苗安全性主动与被动监测[J].职业与健康,2012,28(24):3125-3127.
[12]王亚丽,董锋,王丹,等.美国疫苗上市后安全性监测给我们的启示[J].中国药事,2015,29(9):908-911.
[13]黄巍,周晓红,席胜,等.两种EV71型灭活疫苗安全性比较[J].预防医学,2018,30(4):356-358.
[14]刘世科,陈伟,王帆,等.婴幼儿接种EV71疫苗的安全性观察[J].预防医学,2019,31(5):505-507.
[15]戚小华,李倩,凌罗亚,等.浙江省2010—2012年麻疹成分疫苗疑似预防接种异常反应监测分析[J].国际流行病学传染病学杂志,2013,40(5):317-320.
[16]孙肖瑜,魏晶娇,李万仓,等.温州市EV71灭活疫苗的疑似预防接种异常反应分析[J].预防医学,2018,30(6):629- 630.
[1] 罗美玲,张瑛,刘浩. 长沙市城区居民成人疫苗接种率及影响因素分析[J]. 预防医学, 2019, 31(11): 1128-1130.
[2] 熊素娟,江湖大川 综述;易槐明 审校. 疫苗犹豫影响因素研究进展[J]. 预防医学, 2019, 31(11): 1120-1123.
[3] 武晶,康毓,田丽娜,王中战,张建军,张卫. 丰台区预防接种门诊医护人员推荐接种第二类疫苗意愿调查[J]. 预防医学, 2019, 31(11): 1143-1146.
[4] 李萍萍, 袁芳, 吴锋, 叶莉霞. 2型糖尿病患者流感疫苗接种综合干预效果评价[J]. 预防医学, 2019, 31(9): 930-932.
[5] 黄琳娟, 郑翔, 刘令初, 邱春华, 李波, 陈泽青, 王豪杰, 吴振宇, 王欣. 椒江区老年人群流感疫苗免费接种意愿及影响因素分析[J]. 预防医学, 2019, 31(8): 806-809.
[6] 潘爱珍, 顾丽华, 李敏红, 韩宗梅, 徐校平. 浙江省第一类疫苗损耗情况分析[J]. 预防医学, 2019, 31(8): 854-856.
[7] 刘世科, 陈伟, 王帆, 胡莉莉, 章海斌, 胡丹标, 黄美林, 葛怡哲. 婴幼儿接种EV71疫苗的安全性观察[J]. 预防医学, 2019, 31(5): 505-507.
[8] 伍小雪, 苟晓琴, 石渝, 张柯, 钱媛, 苏敏, 黄俊琼. 人用H7N9禽流感灭活疫苗免疫效果评价的Meta分析[J]. 预防医学, 2019, 31(3): 265-270.
[9] 孙景, 李依恬, 初艳慧. 西城区3岁以下儿童EV71疫苗接种影响因素分析[J]. 预防医学, 2019, 31(1): 46-50.
[10] 姚亚萍, 付国华, 顾丽华, 耿卫勇, 徐旭卿. 犬伤门诊疫苗全程冷链温度监测结果分析[J]. 预防医学, 2018, 30(11): 1169-1171.
[11] 胡昱,陈雅萍,梁辉,汪颖. 男性人群对人乳头瘤病毒疫苗接受度的Meta分析[J]. 预防医学, 2018, 30(9): 897-901.
[12] 王富良,刘仕俊,孙向珏,杜渐. 一起脊髓灰质炎减毒活疫苗接种偶合死亡案例分析[J]. 预防医学, 2018, 30(9): 943-945.
[13] 蒋薇薇,崔光辉,李岩岩,时照华,祖萍. 蜀山区儿童疑似预防接种异常反应监测分析[J]. 预防医学, 2018, 30(8): 789-793.
[14] 孙肖瑜,魏晶娇,李万仓,王志刚,陈玲萍,郑晓春. 温州市EV71灭活疫苗的疑似预防接种异常反应分析[J]. 预防医学, 2018, 30(6): 629-630.
[15] 黄巍,周晓红,席胜军,朱建慧,桂娟娟,王婷婷. 两种EV71型灭活疫苗安全性比较[J]. 预防医学, 2018, 30(4): 356-358.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed